From the Guidelines
Missing weekly Humira (adalimumab) doses since 2018 can lead to reduced effectiveness of the medication and potential disease flares, but does not directly increase your cancer risk. The main risks of inconsistent Humira use include loss of treatment response, worsening of your underlying condition (such as rheumatoid arthritis, Crohn's disease, or psoriasis), and possible development of antibodies against the medication that can make it less effective over time 1. If you've been missing doses regularly, you should discuss this with your healthcare provider immediately to evaluate your current disease status and determine if your treatment plan needs adjustment.
Regarding cancer risk, Humira carries a small increased risk of certain cancers (particularly lymphomas) whether taken consistently or not, as it works by suppressing parts of your immune system 1. This risk is present with consistent use and is not specifically increased by missed doses. The benefits of treating your underlying inflammatory condition typically outweigh these risks for most patients. Your doctor can help assess your individual risk factors and may recommend regular screening tests to monitor for any potential complications.
Some key points to consider:
- Adalimumab has demonstrated efficacy in adults in RCTs and in children in trials with open-label induction and randomized dose-ranging maintenance therapy 1.
- The recommended starting dose of adalimumab is 80 mg taken as 2 self-administered subcutaneous 40-mg injections of the initial dose, followed by a 40-mg self-administered subcutaneous injection 1 wk later, followed by 40 mg self-administered every 2 wk thereafter 1.
- A maintenance dose of adalimumab 40 mg/wk is recommended for better disease control in some patients 1.
- It is essential to discuss your situation with your healthcare provider to determine the best course of action and to assess your individual risk factors 1.
From the FDA Drug Label
For children and adults taking Tumor Necrosis Factor (TNF)-blockers, including HUMIRA, the chances of getting cancer may increase There have been cases of unusual cancers in children, teenagers, and young adults using TNF-blockers. People with rheumatoid arthritis (RA), especially more serious RA, may have a higher chance for getting a kind of cancer called lymphoma. If you use TNF blockers including HUMIRA your chance of getting two types of skin cancer may increase (basal cell cancer and squamous cell cancer of the skin) These types of cancer are generally not life-threatening if treated. Tell your doctor if you have a bump or open sore that does not heal. Some people receiving TNF blockers including HUMIRA developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death.
The risks of missing weekly Humira doses since 2018 are not directly stated in the label, but it is known that Humira can increase the risk of cancer. The label states that people taking TNF-blockers, including Humira, may have a higher chance of getting certain types of cancer, such as lymphoma and skin cancer.
- Key points to consider:
- Humira can increase the risk of cancer
- Certain types of cancer, such as lymphoma and skin cancer, may be more likely to occur in people taking Humira
- It is essential to discuss any concerns about cancer risk with your doctor 2 It is crucial to follow the prescribed treatment plan and consult your doctor if you have any questions or concerns about your Humira treatment.
From the Research
Risks of Missing Weekly Humira Doses
- Missing weekly Humira (adalimumab) doses since 2018 may lead to a decrease in the drug's therapeutic effects, potentially causing a flare-up of the underlying condition being treated, such as rheumatoid arthritis or psoriasis.
- However, there is no direct evidence to suggest that missing doses of Humira increases the risk of developing cancer 3, 4.
Cancer Risk Associated with Humira
- Adalimumab has been associated with an increased risk of rare serious infections, including the reactivation of tuberculosis, and a two-fold risk of serious infections, as reported in the Premier trial 3.
- There is also a risk of promoting lymphoma, although this is considered a rare side effect 3.
- A case report suggests that adalimumab may induce lupus autoantibodies in a psoriasis patient, but this is not directly related to an increased risk of cancer 5.
- Another study found that adalimumab did not promote further metastases in a patient with metastatic breast cancer, and may have even contributed to the stability of healed metastatic bone lesions 4.
Health Anxiety and Humira
- Health anxiety over cancer due to Humira use is understandable, given the potential risks associated with the drug.
- However, it is essential to weigh these risks against the benefits of treatment and to discuss any concerns with a healthcare provider.
- Regular monitoring and follow-up appointments can help to minimize the risks associated with Humira and address any concerns or anxiety related to its use 6, 7.